| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Kamada Ltd.$7.12
-0.03 (-0.42%)
C 50Pipeline Score Undervalued Biotech · Clinical
Market Cap
451.68 M
EPS
0.38
P/E Ratio
20.9 $
Value Trade
441.80 K
-2.12 %
Week
-5.78 %
1 Month
-8.74 %
3 Month
15.83 %
6 Month
29 %
5 Year
-15.35 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
10.24 K
52 Week Range
6.50 - 9.35
% held by Insiders
45.48 %
% held by Institutions
14.61 %
Enterprise Value
389.97 M
Total Shares
57.51 M
Short %
0.36 %
Float Shares
31.40 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kamada Ltd.
487Total events
6Upcoming
115Tier-1 (high impact)
2015 – 2028Coverage
Upcoming catalysts 6
2026
T2Quarterly Update
Affirmed 2026 annual guidance: revenue $200M-$205M, adjusted EBITDA $50M-$53M
2028
T2Other Regulator Milestone
Expected launch of 11 biosimilar products upon Israeli regulatory approval through 2028
2028
T2EU MAA Submission
Eleven biosimilar products expected to be launched in Israel through 2028, subject to EMA and Israeli Ministry of Health approvals
TBD
T2Other Regulator Milestone
Kamada intends to seek EMA inspection and approval for San Antonio center
Event history 481
Jun 1, 2026
▲FDA ApprovalFDA Decision
FDA approval of new in-house RFFIT laboratory for rabies potency testing
Jun 1, 2026
▲Other Regulator MilestoneEx-US Regulatory
Israeli Ministry of Health approval of new RFFIT laboratory
Mar 26, 2026
▲FDA ApprovalFDA Decision
FDA approval of Kamada Plasma's collection center in San Antonio, TX
plasma collection centersource ↗
Mar 11, 2026
▲Partnership / LicenseCorporate
Extended Canadian Blood Services tender for WINRHO, HEPAGAM, CYTOGAM, VARIZIG for two years
Mar 11, 2026
▲Equity OfferingCorporate
Adopted annual cash dividend policy and declared $0.25 per share dividend
Mar 11, 2026
●Oral PresentationPresentation
Conference call and live webcast to discuss 2025 financial results
Mar 2026
▼Trial DiscontinuedTrial
Termination of Phase 3 InnovAATe clinical trial
Alpha-1 Antitrypsin Deficiencysource ↗
Mar 2026
◆Quarterly UpdateCorporate
2025 financial results to be published in first half of March 2026
Mar 2026
▲Partnership / LicenseKEDRABApprovedCorporate
Kedrion exercises option to extend KEDRAB distribution agreement through March 2026
Rabies post-exposure prophylaxissource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $1.8B
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored3.9x
rNPV / MCap Top 76%
Micro Cap (rank 220 of 911)
Percentile RankKamada Ltd. carries a moderate pipeline score (50/100), with $7.3B risk-adjusted pipeline value, led by AAT in Type 1 Diabetes (Phase 2), across $165B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AAT Small molecule | Type 1 Diabetes | Phase 2 | NCT01661192 | 43% | $4.8B | COMPLETED | 12 | - | - | Jan 1, 2017 | - | Jan 11, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Plasma-Derived Hyperimmune Globulin (IgG) | COVID-19 | Phase 1/2 | 2021-03-31 | total patients: 12; patients recovered: 11; discharged by day 5: 7; discharged by day 9: 4 Read More | Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) As Previously Reported, 11 of the 12 Patients Recovered an Read More | |
Plasma-Derived Hyperimmune Globulin (IgG) | COVID-19 | Phase 1/2 | 2021-03-31 | total patients: 12; patients recovered: 11; discharged by day 5: 7; discharged by day 9: 4 Read More | Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) As Previously Reported, 11 of the 12 Patients Recovered an Read More | |
Plasma-Derived Hyperimmune Globulin (IgG) | COVID-19 | Phase 1/2 | 2021-03-31 | total patients: 12; patients recovered: 11; discharged by day 5: 7; discharged by day 9: 4 Read More | Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) As Previously Reported, 11 of the 12 Patients Recovered an Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KMDA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KMDA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of
Kamada Ltd. will hold its Annual General Meeting of Shareholders at its office in Rehovot, Israel, on August 5, 2026. Shareholders are invited to consider the re-election of directors, approval of options for director nominees, and to review financial statements for the year ended December 31, 2025. The Board recommends a vote in favor of all proposals, encouraging full participation from shareholders. The meeting's outcomes will directly influence the company’s governance and future direction.
Read more →KMDAKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Kamada Ltd. has received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, enhancing its capabilities in rabies-neutralizing antibody testing. This facility, located in Beit Kama, Israel, will improve the quality control processes for its products KEDRAB and KAMRAB. The lab is designed to meet high safety and quality standards, reflecting Kamada's commitment to scientific excellence.
Read more →KMDA▼ -6.8%on this news
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Kamada Ltd. reported a revenue increase of 3% year-over-year for Q1-2026, totaling $45.2 million, with an adjusted EBITDA margin of 26%. The company reaffirmed its annual guidance of $200-$205 million in revenues and $50-$53 million in adjusted EBITDA, citing increased underlying demand for its products. A temporary shipment delay affected Q1 results, but overall growth expectations remain strong.
Read more →KMDAKamada to Announce First Quarter 2026 Financial Results on
Kamada Ltd. announced its upcoming financial results for the first quarter of 2026, set to be released on May 13, 2026, prior to U.S. market opening. The company will host a conference call at 8:30 AM ET on the same day to discuss these results with the investment community. Kamada, known for its specialty plasma-derived therapies, is focusing on growth through its product portfolio, plasma collection operations, and potential mergers and acquisitions.
Read more →KMDAKamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Kamada Ltd. announced a cash dividend of $0.25 per share, totaling approximately $14.4 million, set for payment on April 7, 2026. The Israel Tax Authority has granted a ruling allowing eligible shareholders to benefit from a reduced withholding tax rate. Shareholders are advised to consult tax advisors and submit required documentation by May 9, 2026.
Read more →KMDAKamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Kamada Ltd. has received FDA approval for its plasma collection center in San Antonio, Texas. The facility is designed to collect both normal and specialty plasma, with an annual capacity of approximately 50,000 liters. It is expected to generate significant revenue and become one of the largest centers for specialty plasma in the U.S. Kamada plans to seek EMA approval for the site as well.
Read more →KMDAKamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
Kamada Ltd. reported impressive financial results for 2025, achieving record revenues and EBITDA, reflecting a robust growth trajectory. The company maintains a positive outlook for 2026, reiterating revenue and EBITDA guidance that indicates continued expansion. A new annual cash dividend policy was introduced, further demonstrating Kamada's strong financial position. However, the company faced challenges with a decline in gross margin and a decrease in operating cash flow compared to the previous year.
Read more →KMDAKamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel, and HOBOKEN, NJ
Kamada Ltd. has declared a cash dividend of $0.25 per share, to be distributed on April 6, 2026, in line with its newly adopted annual cash dividend policy. The company reported record revenue and profitability for the full year 2025, which contributes to their strong financial position. This dividend is part of Kamada's strategy to reinforce shareholder confidence and facilitate future investments and growth initiatives.
Read more →KMDAKamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Kamada Ltd. will release its financial results for Q4 and fiscal year 2025 on March 11, 2026. The announcement includes a conference call for investors to discuss the results. Kamada is recognized for its specialty plasma-derived products and aims for profitable growth through various strategic initiatives.
Read more →KMDA▲ +5.8%on this news
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. has announced its financial guidance for 2026, projecting revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting double-digit growth. The forecast is based on the continued organic growth of its diverse product portfolio across multiple markets. The company also reaffirmed its 2025 guidance, indicating strong operational performance and cash flow. However, it faces potential challenges from reduced royalty payments and geopolitical risks.
Read more →KMDAKamada Announces a $10-$14 Million Extension of Canadian Supply Tender Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived Products Supply Extension Secures Ongo
Kamada Ltd. has received a $10-$14 million extension of an existing supply tender awarded by Canadian Blood Services for four specialty plasma-derived products. This extension will ensure ongoing sales in Canada for two additional years, valued between Q2 2026 and Q1 2028. The company expressed optimism regarding significant commercial potential for its specialty immunoglobulin portfolio and continues to anticipate growth in revenues and profitability moving forward. The CEO highlighted the importance of this award in affirming their market leadership in specialty plasma-derived therapies.
Read more →KMDAKAMADA LTD. COMPENSATION POLICY FOR OFFICE HOLDERS 1. Purpose This Compensation Policy (the " Policy ") constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada Ltd. (the " Company ")
Kamada Ltd. has outlined its Compensation Policy for Office Holders, which aims to define the terms of office and engagement according to the Companies Law. This policy considers various factors influencing compensation packages for executives and directors, including market practices and applicable laws. Additionally, it includes provisions for adjustments and repayment obligations in case of inaccuracies in financial reporting. The company plans to adopt this policy to provide clear structure and guidance for compensation management.
Read more →KMDAKamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 Based on the Results of a Planned Inte
Kamada Ltd. has announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT, as the independent Data and Safety Monitoring Board indicated it is unlikely to succeed in demonstrating a statistically significant benefit in lung function. Despite this setback, the company remains optimistic regarding its financial outlook, reiterating its revenue guidance for 2025 and projecting double-digit growth for 2026. These projections are based on the company's diverse portfolio of products and planned expansions in their operational capabilities.
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel Dear Shareholder: On
Kamada Ltd. announced the scheduling of its Annual General Meeting of Shareholders on December 10, 2025. The company will discuss an amended Compensation Policy for Executive Officers and Directors, which incorporates feedback from a leading Israeli proxy advisor. Key changes include revised limits on equity-based compensation and new provisions regarding vesting upon termination or change of control. All shareholders are invited to attend and engage in discussions regarding the company’s financial performance and governance matters.
Read more →KMDA▲ +5.4%on this news
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
Kamada Ltd. reported strong financial results for Q3 and the first nine months of 2025, with total revenues of $135.8 million, an 11% year-over-year increase. The company also announced a 35% rise in adjusted EBITDA, reaching $34.2 million. Kamada reiterated its full-year revenue guidance and highlighted ongoing clinical trials and plasma collection initiatives.
Read more →KMDAKamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation
Kamada Ltd. has announced the enrollment of the first patient in a clinical trial for CYTOGAM, aimed at preventing late Cytomegalovirus (CMV) infections in kidney transplant recipients. The SHIELD study will explore the efficacy of CYTOGAM in high-risk patients who are CMV seronegative and have a CMV seropositive donor. This trial is led by recognized experts in the field, highlighting the importance of addressing CMV-related complications in transplant care.
Read more →KMDAKamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
Kamada Ltd. will release its financial results for Q3 and nine months ended September 30, 2025, on November 10, 2025. An investment community conference call will follow to discuss these results. The company is focused on growth through its marketed products and expanding its plasma collection operations.
Read more →KMDAKamada to Present at the Stifel 2025 Healthcare Conference
Kamada Ltd. announced that its CEO, Amir London, will present at the Stifel 2025 Healthcare Conference on November 12, 2025. The event will take place at the Lotte New York Palace Hotel, and Mr. London will also be available for one-on-one investor meetings. Kamada is focused on growth through its portfolio of specialty plasma-derived products and expanding its plasma collection operations.
Read more →KMDAKamada to Participate in Upcoming September Investor Conferences
Kamada Ltd. will participate in two upcoming investor conferences in September 2025. CEO Amir London is scheduled to present at the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference. Both events will include opportunities for one-on-one meetings with investors, highlighting the company's commitment to engaging with stakeholders.
Read more →KMDAKamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance First Half 2025 Tota
Kamada Ltd. announced strong financial results for the second quarter and first half of 2025, reporting an 11% increase in total revenue year-over-year, totaling $88.8 million. Adjusted EBITDA rose by 35% to $22.5 million, which translates to a 25% margin. The company has raised its annual adjusted EBITDA guidance based on robust financial performance and a positive outlook for the remainder of the year. Furthermore, Kamada received FDA approval for a new plasma collection center, expected to significantly contribute to future revenues.
Read more →KMDAKamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
Kamada Ltd. has received FDA approval for its plasma collection center in Houston, Texas, allowing it to begin commercial sales of normal source plasma. The facility, which supports 50 donor beds, is expected to have an annual capacity of approximately 50,000 liters. Kamada plans to seek further approval from the European Medicines Agency for this site. The Houston center is part of Kamada's strategy to enhance its plasma collection operations across Texas.
Read more →KMDAKamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
Kamada Ltd. will release its financial results for the second quarter and first half of 2025 on August 13, 2025. The announcement includes a conference call for the investment community to discuss the results. Kamada continues to focus on growth through its portfolio of plasma-derived products and expansion of plasma collection operations.
Read more →KMDAKamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
Kamada Ltd. has confirmed that its operations and product availability remain stable despite ongoing events in the Middle East. The company is focused on business continuity and has sufficient product levels in distribution centers outside Israel. CEO Amir London reassured stakeholders that they do not foresee any shortages in meeting client demands.
Read more →KMDAKamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-
Kamada Ltd. reported strong first quarter 2025 financial results, achieving a 17% increase in revenues year-over-year, totaling $44 million, alongside a 54% rise in adjusted EBITDA. The company's Chief Executive Officer emphasized that the results are consistent with previous expectations, highlighting profitable growth driven by a diverse product portfolio. Kamada is maintaining its 2025 revenue guidance between $178 million to $182 million and is actively investing in strategic growth areas, including plasma collection and clinical trials. Additionally, the company has initiated a post-marketing research program for CYTOGAM, aiming to advance its product utilization in the market.
Read more →KMDAKamada to Announce First Quarter 2025 Financial Results on
Kamada Ltd. will announce its financial results for Q1 2025 on May 14, prior to the U.S. market opening. The company will host a conference call at 8:30am ET to discuss the results. Kamada continues to focus on growth through product commercialization and expanding plasma collection operations, indicating robust operational strategies in place.
Read more →KMDAKamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM in the Management of Cytomegalovirus (CMV) in Solid Organ
Kamada Ltd. has launched a comprehensive post-marketing research program for its product CYTOGAM, aimed at better managing cytomegalovirus (CMV) in solid organ transplantation. This program seeks to generate new data supporting the benefits of CYTOGAM and will involve various innovative strategies and collaborations with clinical experts. The initiative follows the FDA's approval of Kamada's manufacturing capabilities for CYTOGAM, and recent clinical studies have shown promising results regarding its effectiveness. The company reported a significant revenue increase from CYTOGAM sales, highlighting its strong market position.
Read more →KMDA▲ +5.7%on this news
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders REHOVOT, Israel, and HOBOKEN, NJ
Kamada Ltd. announced a special cash dividend of $0.20 per share, totaling approximately $11.5 million, expected to be paid on April 7, 2025. The company has obtained a tax ruling from the Israel Tax Authority that may allow eligible shareholders to benefit from reduced withholding tax rates on this dividend. Shareholders must ensure compliance with the terms outlined in the ruling to receive the tax benefits. The announcement highlights the company's commitment to profitable growth and strategic development in the biopharmaceutical sector.
Read more →KMDAKamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Lit
Kamada Ltd. announced the opening of a new plasma collection center in San Antonio, Texas, which will enhance its operations. The center is designed to support around 50 donor beds with an estimated annual capacity of 50,000 liters. This expansion aims to meet the rising demand for hyper-immune plasma and is projected to generate annual revenues of $8 million to $10 million at full capacity. Kamada plans to submit approval applications for the new site to both the U.S. FDA and the European Medicines Agency in the second half of 2025.
Read more →KMDA▲ +7.4%on this news
Kamada Declares Special Cash Dividend of $0.20 Per Share Company Reports Record Revenue and Profitability for Full-Year 2024 REHOVOT, Israel, and HOBOKEN, NJ
Kamada Ltd. has announced a special cash dividend of $0.20 per share, totaling approximately $11.5 million, marking the first dividend payment in the company's history. This decision follows a strong financial performance in 2024, during which the company achieved record revenue and profitability. CEO Amir London highlighted the company's robust liquidity and confidence in its growth strategy, focusing on commercial expansion, business development, and advancements in its lead product candidate, Inhaled AAT. The dividend is set to be paid on April 7, 2025, to shareholders recorded by March 17, 2025.
Read more →KMDA▲ +7.4%on this news
Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth
Kamada Ltd. reported stellar financial results for 2024, achieving record revenues of $161.0 million and a 42% increase in adjusted EBITDA compared to the previous year. The company reaffirmed its 2025 revenue guidance of $178 to $182 million, anticipating further growth driven by its broad product portfolio. Notably, net income surged to $14.5 million, a 75% boost year-on-year. Despite a dip in net income in Q4 2024, Kamada remains optimistic about its growth trajectory and has declared a special cash dividend of $0.20 per share.
Read more →KMDAKamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on
Kamada Ltd. announced that it will release its financial results for the fourth quarter and fiscal year ending December 31, 2024, on March 5, 2025. The company will also host a conference call at 8:00am ET on the same date to discuss these results and engage with shareholders and interested parties. Known for its portfolio of plasma-derived therapies, Kamada is focused on growth through commercial activities, business development, and expansion of its plasma collection operations.
Read more →KMDA▲ +6.4%on this news
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB and VARIZIG in Latin America REHOVOT, Israel, and HOBOKEN, NJ
Kamada Ltd. has secured a $25 million three-year contract for the supply of its products KAMRAB and VARIZIG in Latin America. This agreement is expected to contribute to the company's revenue guidance for 2025 and emphasizes the commercial potential of its specialty immunoglobulin portfolio. CEO Amir London highlighted that winning this tender reflects the strength of their product offerings in international markets. Kamada aims to pursue further commercial contracts in strategic territories as part of its growth strategy.
Read more →KMDA▲ +7.6%on this news
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Re
Kamada Ltd. has affirmed its financial guidance for 2024, projecting revenues of $158 million to $162 million and adjusted EBITDA between $32 million and $35 million. The company is optimistic about 2025, forecasting revenue growth of 13% and a rise in adjusted EBITDA by 19%, with estimates between $178 million to $182 million in revenue. Kamada also aims to expand its plasma collection operations with a new site in San Antonio, Texas, projected to contribute significant annual revenue. Additionally, a regulatory agreement from the FDA on a key clinical trial is expected to streamline the process and reduce the study's patient count.
Read more →KMDAKamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance Revenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-
Kamada Ltd. announced strong financial results for the third quarter and nine months ended September 30, 2024, showing significant growth in revenues and adjusted EBITDA. Total revenues reached $121.9 million for the first nine months, a 15% increase compared to the previous year. The company also raised its full-year adjusted EBITDA guidance from $28-32 million to $32-35 million, citing continued operational strength and upcoming growth drivers. Kamada highlighted the expansion of its plasma collection operations with a new center in Houston, TX, which is set to become a major site for specialty plasma collection.
Read more →KMDAKamada to Announce Third Quarter and Nine-Months Ended
Kamada Ltd. is scheduled to announce its third-quarter and nine-month financial results for the period ending September 30, 2024, prior to the opening of U.S. markets on November 13, 2024. The company will also hold a conference call to discuss these results and answer questions from shareholders. Kamada is known for its portfolio of plasma-derived biopharmaceutical products and is advancing its innovative development pipeline, which targets areas with unmet medical needs, thus indicating ongoing investment in research and development.
Read more →KMDAKamada to Present at the Stifel 2024 Healthcare Conference REHOVOT, Israel, and HOBOKEN, NJ
Kamada Ltd. (NASDAQ: KMDA) announced that its CEO, Amir London, will present a corporate overview at the upcoming Stifel 2024 Healthcare Conference in New York on November 18, 2024. The company is recognized for its portfolio of products aimed at rare and serious conditions and is active in the specialty plasma-derived sector. Kamada is also pursuing innovative product development and will make a live webcast of the event available on its investor relations webpage.
Read more →KMDAKamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,00
Kamada Ltd. announced the opening of a new plasma collection center in Houston, Texas, expanding their operational capabilities in the U.S. This 12,000 square foot site, aimed at supporting over 50 donor beds, is designed to have an annual collection capacity of around 50,000 liters. The company plans to submit regulatory approvals to the FDA and EMA in 2025 as they enhance their plasma collection operations. Additionally, Kamada has begun construction on a third plasma collection site in San Antonio, anticipated to boost their capacity further.
Read more →KMDAKamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability Revenues for Second Quarter of 2024 were $42.5 Million, up
Kamada Ltd. reported robust financial results for the second quarter and first half of 2024, showcasing an 18% increase in top-line growth and a significant 68% upswing in adjusted EBITDA. The total revenues for the first half amounted to $80.2 million, with a strong cash flow of $15 million generated from operations. The company reiterated its full-year guidance, projecting revenues between $158 million to $162 million, and is advancing its pivotal Phase 3 clinical trial for an inhaled therapy. CEO Amir London expressed confidence in continued growth through diverse commercial catalysts and business development opportunities.
Read more →KMDAKamada to Announce Second Quarter and First Half Ended
Kamada Ltd. has announced it will release its financial results for the second quarter and first half ending June 30, 2024, prior to the opening of the U.S. financial markets on August 14, 2024. The company will also host a conference call for investors to discuss the results and address questions. Kamada is known for its range of plasma-derived biopharmaceutical products and is advancing a clinical trial for its inhaled AAT treatment targeting AAT deficiency. With strategic partnerships, it distributes its products across various countries, aiming for profitable growth in the biopharmaceutical sector.
Read more →KMDAKamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance Revenues for First Quarter of 2024 were $37.7
Kamada Ltd. reported strong financial results for the first quarter of 2024, achieving a 23% increase in total revenues year-over-year, amounting to $37.7 million. Adjusted EBITDA reached $7.5 million, nearly doubling from the previous year and resulting in a 20% margin. The company has raised its full-year revenue guidance, reflecting its optimistic outlook driven by key products KEDRAB and CYTOGAM. Kamada continues to negotiate business development opportunities and is advancing its clinical trial for inhaled Alpha-1 Antitrypsin therapy.
Read more →KMDAKamada to Announce First Quarter 2024 Financial Results and Host Conference Call on
Kamada Ltd. announced that it will release its first-quarter financial results for 2024 on May 8, 2024, prior to the opening of U.S. financial markets. The company will host a conference call on the same day to discuss these results and engage with investors. Kamada focuses on rare medical conditions, leveraging its portfolio of FDA-approved products and an innovative development pipeline aimed at significant unmet medical needs.
Read more →KMDA▼ -5%on this news
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd. reported a successful performance in 2023, achieving total revenues of $142.5 million and adjusted EBITDA growth of 35% compared to the previous year. The company anticipates continued growth in 2024, with revenue guidance indicating a rise to $156 million to $160 million. Key drivers include increased sales of their anti-rabies immunoglobulin product KEDRAB and positive developments in their Inhaled AAT product candidate. The company has also strengthened its distribution agreements and is expanding its market presence internationally.
Read more →KMDA▼ -5%on this news
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability Total Revenues for Fiscal Year 2023 of $142.
Kamada Ltd. reported strong financial results for the fiscal year 2023, achieving total revenues of $142.5 million, a 10% increase from the previous year. The company announced an adjusted EBITDA of $24.1 million, which reflects a 35% year-over-year growth. Kamada has also provided optimistic guidance for 2024, projecting revenues between $156 million to $160 million. Significant sales growth for its anti-rabies product KEDRAB is expected to continue, bolstered by a new distribution agreement. The company is also advancing clinical trials for its Alpha-1 Antitrypsin therapy.
Read more →KMDAKamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on
Kamada Ltd. has announced the upcoming release of its financial results for the fourth quarter and fiscal year 2023, scheduled for March 6, 2024. In addition, the company will provide financial guidance for 2024. A conference call will be held at 8:30 AM ET on the same day to discuss these results with investors and interested parties. The company focuses on treating rare serious conditions and has a strong pipeline in plasma-derived products.
Read more →KMDA▲ +20.9%on this news
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB including $180 Million of Revenues Over First Four Years Largest Commercial Agreement in Kamada's His
Kamada Ltd. has announced a significant commercial agreement with Kedrion for the U.S. distribution of KEDRAB, introducing projected revenues of approximately $180 million over the first four years. This agreement, starting in January 2024, marks Kamada's largest to date and highlights the expected growth of KEDRAB's market share. Both companies aim to enhance the distribution of KEDRAB and other Kedrion products, with plans for potential expansion into additional territories. Kamada anticipates a substantial increase in sales of KEDRAB for the full year 2023 due to this collaboration.
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meet
Kamada Ltd. has announced its upcoming Annual General Meeting scheduled for December 28, 2023, in Rehovot, Israel. Key agenda items include the re-election of seven directors and approval of a salary increase for the CEO. Shareholders of record are encouraged to participate either in person or by proxy to ensure their votes count in the decision-making process. The meeting will also cover the company's consolidated financial performance for 2022.
Read more →KMDAKamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance Third Quarter 2023 Revenues were $37.9 Million Representing an 1
Kamada Ltd. reported strong financial results for Q3 and the first nine months of 2023, with revenues of $106.1 million, marking a 26% increase year-over-year. The company also saw a 67% rise in adjusted EBITDA, reaching $17.7 million. Key growth drivers include sales of their anti-rabies immunoglobulin product, KEDRAB, and the advanced status of their pivotal phase 3 InnovAATe trial for Inhaled AAT. Kamada reaffirmed its full-year revenue guidance between $138 million to $146 million and expressed optimism about sustained profitability growth in the fourth quarter.
Read more →KMDAKamada to Announce Third Quarter and First Nine Months Ended
Kamada Ltd. (NASDAQ & TASE: KMDA) announced that it will release its financial results for the third quarter and the first nine months ending September 30, 2023, before the U.S. market opens on November 13, 2023. The company will host a conference call to discuss these results at 8:30 am Eastern Time on the same date. Kamada is noted for its commercial-stage biopharmaceutical products focused on rare conditions and has a significant presence in the specialty plasma-derived market.
Read more →KMDAKamada Announces Recent Achievements with CYTOGAM including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data Following Recent FDA Approval of Technology Tr
Kamada Ltd. has announced significant achievements concerning CYTOGAM, its FDA-approved immunoglobulin product now available for commercial sale in the U.S. The transition of manufacturing from CSL Behring to Kamada's facility enhances product accessibility. New clinical data presented at IDWeek 2023 demonstrates the effectiveness of CYTOGAM in preventing cytomegalovirus disease among high-risk lung transplant patients. Additionally, the company has formed a Scientific Advisory Board to advance research in solid organ transplantation.
Read more →KMDAKamada Provides Corporate Update on its Israel Operations Rehovot, Israel, and Hoboken, NJ
Kamada Ltd. has provided an update regarding its ongoing operations in Israel amid recent events. The company reports that its business activities continue without interruption and anticipates that its global product supply will also be stable. Kamada's leadership expressed condolences for those affected by the recent violence while reaffirming support for its employees. Future updates will be provided as the situation evolves.
Read more →KMDAKamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strat
Kamada Ltd. announced the approval and upcoming closure of a $60 million private placement with FIMI Opportunity Funds. Following the agreement, FIMI will become a controlling shareholder, owning approximately 38% of Kamada’s outstanding shares. The injection of funds is expected to bolster Kamada's financial position, enabling the company to pursue new growth and business development opportunities. Additionally, Kamada has appointed two new independent directors to its Board, enhancing its governance and strategic oversight.
Read more →KMDAKamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year;
Kamada Ltd. reported strong financial results for the second quarter and first half of 2023, with a 59% year-over-year revenue increase in Q2, totaling $37.4 million. Adjusted EBITDA grew 24% year-over-year, reaching $9.9 million. The company reiterated its full-year guidance, expecting revenues between $138 million and $146 million. Kamada continues to advance its pivotal Phase 3 InnovAATe trial for Inhaled AAT, receiving positive feedback from the European Medicines Agency regarding the trial design. The company also seeks shareholder approval for a $60 million share purchase agreement to enhance financial flexibility.
Read more →KMDArespectively, to our Report on Form 6 -K /A on May 24, 2023, and are incorporated herein by reference. Dilution and Impact on Existing Shareholders The issuance of the ordinary shares to the FIMI Funds in t
Kamada Ltd. is holding an Extraordinary General Meeting of Shareholders on August 29, 2023, to vote on a proposed $60 million private placement with FIMI Opportunity Funds. If approved, this transaction will result in FIMI becoming the controlling shareholder of Kamada. The agenda includes the election of external directors and the granting of options to them, contingent on the approval of the Private Placement. The meeting will also address voting procedures and shareholder eligibility.
Read more →KMDAKa mada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB Distribution Agreement in the U.S. The Extended Agreement Term is Until March 2026 The Company Generated Approximately $16 Million in Revenu
Kamada Ltd. announced that Kedrion has exercised an option to extend their KEDRAB distribution agreement in the U.S., now valid until March 2026. This partnership is vital for promoting KEDRAB, indicated for rabies post-exposure prophylaxis. The agreement's extension comes with expectations for significant sales growth in 2023, following $16 million in revenue generated from KEDRAB distribution in 2022. Discussions for potential collaboration scope expansion are also underway.
Read more →KMDAKamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB Distribution Agreement in the U.S.
Kamada Ltd. announced that Kedrion has exercised its option to extend the distribution agreement for KEDRAB until March 2026. This extension is expected to drive revenue growth, with Kamada having generated approximately $16 million from KEDRAB sales in 2022. The company anticipates a significant increase in sales for 2023, highlighting their confidence in the product's market potential.
Read more →KMDA▲ +15.4%on this news
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-Year First Quarter 2023 EBITDA of $3.
Kamada Ltd. reported its financial results for the first quarter of 2023, achieving total revenues of $30.7 million, which marks a 9% increase from the previous year. The company's EBITDA grew by 16% year-over-year to reach $3.8 million. Kamada also reaffirmed its fiscal year 2023 revenue guidance, expecting to generate between $138 million and $146 million, with a projected EBITDA of $22 million to $26 million, reflecting over 30% profitability growth compared to 2022. The company highlighted successful sales of multiple products and progress in its clinical trials, including for inhaled AAT therapy.
Read more →KMDA▲ +15.4%on this news
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds Funding to Support Kamada's Growth Plans and Execution of Strategic Business Development Opportunities REHOVOT, Israel, and Hoboken, NJ
Kamada Ltd. has announced a $60 million private placement agreement with FIMI Opportunity Funds. This funding is intended to support Kamada's growth plans and strategic business development initiatives. Following the transaction, FIMI will become a controlling shareholder, owning approximately 38% of Kamada's ordinary shares. The completion of the private placement is expected in the second half of 2023, subject to regulatory and shareholder approvals.
Read more →KMDA▲ +15.4%on this news
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary REHOVOT, Israel, and Hoboken, NJ
Kamada Ltd. has announced that Chief Financial Officer Chaime Orlev will remain in his role despite prior intentions to resign. This decision follows a significant $60 million private placement aimed at fostering the company's growth and exploring new business opportunities. Additionally, Nir Livneh has rejoined the company as Vice President, General Counsel, and Corporate Secretary. This move is seen as a strong enhancement to the executive management team as Kamada aims to solidify its position in the specialty plasma-derived biopharmaceutical sector.
Read more →KMDASHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this " Agreement ") is made as of
On May 23, 2023, Kamada Ltd. entered into a Share Purchase Agreement with FIMI Opportunity 7, L.P. and FIMI Israel Opportunity 7, Limited Partnership. The agreement outlines the purchase of shares amounting to a total of $60 million, which is expected to enhance Kamada's capital structure. The details of the transaction include specific issuance of shares and conditions under which the shares are offered. This strategic move may provide Kamada with increased financial stability and opportunities for future growth.
Read more →KMDAKamada to Announce First Quarter 2023 Financial Results and Host Conference Call on
Kamada Ltd. has announced that it will release its financial results for the first quarter of 2023 on May 24, prior to U.S. market opening. The management will host a conference call to discuss the results at 8:30 AM Eastern Time that same day. Kamada, a biopharmaceutical company based in Israel, specializes in plasma-derived products and has a robust portfolio addressing rare conditions. The company continues to focus on growth and has various commercial and investigational products in its pipeline.
Read more →KMDAKamada Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland Switzerland is the first European country to approve Glassia , which received U.S. FDA approv
Kamada Ltd. has received marketing authorization from Swissmedic for its product Glassia, a treatment for Alpha-1 Antitrypsin Deficiency (AATD), marking Switzerland as the first European nation to grant approval. Glassia is intended for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe AATD. The company anticipates launching the product commercially in Switzerland during the second half of 2023, pending necessary reimbursement coverage. They are partnering with IDEOGEN Group to facilitate the commercialization of Glassia in the Swiss market.
Read more →KMDAKamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM at the Company's Facility in Israel Sales of CYTOGAM Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million i
Kamada Ltd. has received U.S. FDA approval to manufacture its product CYTOGAM at its facility in Beit Kama, Israel. This approval marks the successful completion of the technology transfer process from CSL Behring and allows Kamada to enhance its production capabilities. CYTOGAM, indicated for prophylaxis against cytomegalovirus disease in organ transplant recipients, generated approximately $23 million in sales in 2022. The company expects further growth from this and other FDA-approved IgG products in its portfolio.
Read more →KMDAKamada Issues 2023 CEO Letter to Shareholders Rehovot, Israel, and Hoboken, NJ
Kamada Ltd. issued a 2023 CEO letter highlighting a transformative 2022, where the company transitioned from reliance on GLASSIA sales to a diversified specialty plasma business. The company reported total revenues of $129.3 million, a 25% increase from the previous year, and strong cash flow, with expectations for continued growth in 2023. The letter detailed advancements in product offerings, including FDA-approved IgGs, and progress in ongoing clinical trials. Kamada remains optimistic about future developments and financial performance, emphasizing long-term value for shareholders.
Read more →KMDAKamada Files Annual Report for the Year Ended
Kamada Ltd. has filed its annual report for the fiscal year ended December 31, 2022, with the SEC. The report includes audited consolidated financial statements and is accessible on the SEC website as well as Kamada's investor relations website. Kamada focuses on treating rare and serious conditions with its portfolio of FDA-approved plasma-derived products and is also advancing an innovative pipeline. The company has made strides in the Israeli market and is investing in research and development.
Read more →KMDAKamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Grow
Kamada Ltd. reported strong financial results for the fiscal year 2022, achieving total revenues of $129.3 million and EBITDA of $17.8 million, reflecting substantial growth compared to 2021. The company anticipates that momentum will continue into 2023, with guidance for revenues projected between $138 million and $146 million and EBITDA between $22 million and $26 million. The CEO highlighted the company's strategic transformation and growth drivers, suggesting favorable conditions for profitability growth in the future.
Read more →KMDAKamada Issues 2023 CEO Letter to Shareholders
Kamada Ltd. has issued a letter to shareholders highlighting a transformative 2022 that included strong financial performance and a shift towards a diversified specialty plasma company. The company reported total revenues of $129.3 million and a projected growth in 2023 revenues to between $138 million and $146 million. Key developments include advancements in clinical trials, a strong presence in the U.S. market through a dedicated sales team, and expectations of continued growth from multiple product lines. The CEO expresses optimism for sustained double-digit revenue growth in the upcoming years.
Read more →KMDAKamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on
Kamada Ltd. is set to announce its fourth quarter and full year 2022 financial results on March 15, 2023, before the U.S. markets open. The announcement will be followed by a conference call for investors and interested parties to discuss the financial performance and address questions. The company, which is a leader in the specialty plasma-derived field, has a portfolio that includes several FDA-approved products and is also advancing clinical trials for new treatments.
Read more →KMDAKamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM at the Company's Facility in Israel FDA Approval Currently Expected by Mid-2023 Sales of CYTOGAM Highest Among Four IgG Products Acquired
Kamada Ltd. has submitted an application to the U.S. FDA for the manufacture of CYTOGAM at its facility in Israel, with approval anticipated by mid-2023. This application is a part of the technology transfer process from the previous manufacturer, CSL Behring. The company expects significant growth from its portfolio of FDA-approved IgG products in the upcoming year. With sufficient inventory to meet market demand until FDA approval, Kamada plans to initiate commercial manufacturing in the latter half of 2023.
Read more →KMDA▲ +7.5%on this news
Kamada Announces Planned Transition of Chief Financial Officer Rehovot, Israel, and Hoboken, NJ
Kamada Announces Planned Transition of Chief Rehovot, Israel, and Hoboken, NJ - December 19, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that its
Read more →KMDAKamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Ye
Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance Israel, and Hoboken, NJ - November 22, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical compan
Read more →KMDAKAMADA LTD. COMPENSATION POLICY FOR EXECUTIVE OFFICERS 1. Purpose This Compensation Policy (the " Policy ") constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada. Ltd. (the " Compan
COMPENSATION POLICY FOR EXECUTIVE OFFICERS This Compensation Policy (the "Policy") constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada. Ltd. (the "Company") with respect to the determination of Terms of Office and Engagement of Office H
Read more →KMDAKamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to Date Independent Data Safety Moni
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT Rehovot, Israel, and Hoboken, NJ, November 7, 2022 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company focused on speci
Read more →KMDAKamada to Present at the Credit Suisse 31st Annual Healthcare Conference REHOVOT, Israel, and Hoboken, NJ
Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference REHOVOT, Israel, and Hoboken, NJ, - October 26, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announ
Read more →KMDAKamada Awarded $22 Million Extension of Canadian Supply Tender Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021 Supply Extension Secures Ongoing Sales
Kamada Awarded $22 Million Extension of Canadian Rehovot, Israel, and Hoboken, NJ, October 19, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company
Read more →KMDAKamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance Second Quarter 2022
Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance Rehovot, Israel, and Hoboken, NJ - August 17, 2022 -- Kamada Ltd. (NASDAQ
Read more →KMDAKamada Announces Resolution the Labor Strike at the Company's Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed
Kamada Announces Resolution the Labor Strike at the Company's Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed Israel - July 15, 2022 -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on sp
Read more →KMDAKamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed
REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Employees’ Union of Kamada’s Beit Kama produc
Read more →KMDAKamada Announces $11.4 Million International VARIZIG Procurement Agreement Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America Product Supply Expecte
Kamada Announces $11.4 Million International VARIZIG Procurement Agreement Rehovot, Israel, and Hoboken, NJ, July 6, 2022 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announce
Read more →KMDAKamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma Derived Therapeutics Market Rehovot, Israel, and Hoboken, NJ
Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma Derived Therapeutics Market Rehovot, Israel, and Hoboken, NJ, June 15, 2022 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biophar
Read more →KMDAKamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts Rehovot, Israel
Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts Rehovot, Israel, June 1, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announce
Read more →KMDAKamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification REHOVOT, Israel - May 17, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.T
Read more →KMDAKamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022 First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year. Kamada Re
Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022 REHOVOT, Israel - May 17, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, f
Read more →KMDAKamada to Announce First Quarter Ended
Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022 Rehovot, Israel, May 11, 2022 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived
Read more →KMDAKamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022
REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended Marc
Read more →KMDAKamada Ltd. (the " Company ") (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, today announced that on
Ltd. (the "Company") (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, today announced that on April 26, 2022, during the course of the Company's negotiations with the Histadrut - General Federation of Labor in Israel (the "Histadrut") and the Emp
Read more →KMDAKamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022 Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourt
Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022 REHOVOT, Israel - March 15, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmac
Read more →KMDAKamada Issues 2022 CEO Letter to Shareholders
Kamada Issues 2022 CEO Letter to Shareholders REHOVOT, Israel - March 15, 2022 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from
Read more →KMDAKamada Expands U.S. Leadership Team with Two Key Appointments New Executives to Strengthen the Company's U.S. Commercial Operations, Focused on Recently Acquired Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune
Kamada Expands U.S. Leadership Team with Two REHOVOT, Israel - March 14, 2022 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced the appointments of two execut
Read more →KMDAKamada Ltd. (the " Company ") (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that on
(the "Company") (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that on March 3, 2022, during the course of the Company's negotiations with the Histadrut - General Federation of Labor in Israel (the "Histadrut") and the Employees' Committee of
Read more →KMDAKamada to Announce Fourth Quarter and Fiscal Year Ended
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022 Rehovot, Israel, March 2, 2022 -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will r
Read more →KMDAto a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on
Weizmann Science Park Rehovot 7670402, Israel Notice of Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021 (the "Company") today announced that all of the proposals presented for approval at its 2021 Annual General Meeting of Shareholders he
Read more →KMDA▲ +7.5%on this news
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products Third Quarter 20
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products REHOVOT, Israel - November 22, 2021 -- Kamada Ltd. (NASDAQ: KMDA; TASE:
Read more →KMDA▲ +7.5%on this news
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a of Four FDA-Approved Commercial Products REHOVOT, Israel - November 22, 2021 - Kamada Ltd. (NASDAQ: KMDA;
Read more →KMDAKamada to Announce Third Quarter Financial Results and Host Conference Call on
Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021 Rehovot, Israel, November 8, 2021 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the 2021 Annual General M
Weizmann Science Park Rehovot 7670402, Israel OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS cordially invite you to attend the 2021 Annual General Meeting of Shareholders of Kamada Ltd. (the "Meeting") to be held at our offices at 2 Holzman Street, Weizmann Science Park, Reh
Read more →KMDAKamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities Second Quarter 2021 Revenues were $24.2 Million In Connection with the Transition of GLASSIA M
Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities Israel - August 11, 2021 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the th
Read more →KMDAKamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021 Rehovot, Israel, August 5, 2021 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial
Read more →KMDAKedrion and Kamada Announce FDA Approval of KEDRAB Label Update, Confirming Safety and Effectiveness in Children Label Expansion Differentiates KEDRAB as the First and Only Human Rabies Immune Globulin (HRIG) Available i
Kedrion and Kamada Announce FDA Approval of KEDRAB Label Update, Confirming Safety and Effectiveness in Children Lee, NJ and Rehovot, Israel - June 2, 2021 - Kedrion Biopharma and Kamada Ltd. (NASDAQ & TASE: KMDA), two leading biopharmaceutical companies specialized in plasma-
Read more →KMDAKamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 Million In Connection with the Tr
Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities Israel - May 12, 2021 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Ma
Read more →KMDAKamada to Announce First Quarter Ended March 31, 2021 Financial Results and Host Conference Call on May 12, 2021
REHOVOT, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2021, prior to the open of the U.S. financial markets on W
Read more →KMDAKamada Announces Amendment to GLASSIA License Agreement with Takeda Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product's US Biologics License Application (BLA) to Takeda
Kamada Announces Amendment to GLASSIA License Agreement with Takeda Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product's US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021 Kamada to Receive fro
Read more →KMDAKamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) As Previously Reported, 11 of the 12 Patients Recovered an
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) Rehovot, Israel, March 31, 2021 - Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, to
Read more →KMDAKamada to Present at the Jefferies Global Plasma Summit
Kamada to Present at the Jefferies Global REHOVOT, Israel - March 9, 2021 - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies
Read more →KMDAKamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integ
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Activel
Read more →KMDAKamada Files Annual Report for the Year Ended December 31, 2020
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Co
Read more →KMDAKamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities Full-Year 2020 Revenues were $133.2 Million, In-Line with the Company's Guidance; Adjusted EB
Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities Israel - February 10, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the
Read more →KMDAKamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA Transaction Represents Kamada's Entry into U.S. Plasma Collection Market and Advances the Company's Strategic Objec
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA Transaction Represents Kamada's Entry into U.S. Plasma Collection Market and Advances the Company's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma
Read more →KMDAKamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024 Pote
Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel Israel - January 13, 2021 -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that the Company has entered into agreements with two u
Read more →KMDAKamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition; Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Rehovot, Israel
Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition; Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Rehovot, Israel, January 5, 2021 -- Kamada Ltd. (NASDAQ & TASE: KMDA), plas
Read more →KMDAKamada Added to the NASDAQ Biotechnology Index
Kamada Added to the NASDAQ Biotechnology REHOVOT, Israel - December 21, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The an
Read more →KMDAKamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that on
Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that on December 14, 2020, during the course of the Company's negotiations with the Histadrut - General Federation of Labor in Israel (the "Histadrut") and the Employ
Read more →KMDAKamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respe
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development REHOVOT, Israel - November 11, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial r
Read more →KMDAKamada to Announce Third Quarter Ended
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020 Rehovot, Israel, November 4, 2020 -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release fina
Read more →KMDAKamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets o
Read more →KMDAto our Report on Form 6-K on
Weizmann Science Park Rehovot 7670402, Israel OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS cordially invite you to attend the 2020 Annual General Meeting of Shareholders of Kamada Ltd. (the "Meeting") to be held at our offices at 2 Holzman Street, Weizmann Science Park, Reh
Read more →KMDAKamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021 Treatment with Kamad
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021 Rehovot, Israel, October 19, 2020 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a pl
Read more →KMDAKamada Provides Update on 2021 GLASSIA Supply to Takeda Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA to Takeda in 2021 which is Takeda's Minimum Commitment for 2021 Pursuant to the Existing Sup
Kamada Provides Update on 2021 GLASSIA REHOVOT, Israel - October 7, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, it expects to receive approximately $25 million in
Read more →KMDAKamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Di
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) Rehovot, Israel, September 8, 2020 -- K
Read more →KMDAKamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective The Study of KEDRAB (Rabies Immune Globuli
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective Rehovot, Israel and Fort Lee, New Jersey, August 19, 2020 - Kamada Ltd. (NASDAQ & TASE: KMDA) and
Read more →KMDAKamada Announces Changes to its Board of Directors Lilach Asher Topilsky, a Director on the Company's Board and a Senior Partner at FIMI Opportunity Funds, Appointed Chairman Current Chairman, Leon Recanati, Remains on t
Kamada Announces Changes to its Board REHOVOT, Israel - August 12, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Directors. Lilach Asher Topilsky, a Director on the Comp
Read more →KMDAKamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position Second Quarter Revenues were $33.1 million, Compared to $35.3 million in 2019, First Ha
Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position Israel - August 12, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results fo
Read more →KMDAKamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel Study Participants are
Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia
Read more →KMDAKamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on We
Read more →KMDAKamada to Announce Second Quarter Ended
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020 Rehovot, Israel, August 5, 2020 -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial
Read more →KMDAKamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel Kamada Completed Manufacturing and Released the First Batch of its
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel REHOVOT, Israel - June 17, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, t
Read more →KMDAKamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress Total Revenues were $33.3 Million, an Increase of 24% Year-over-Year Net Income was $5.2 Million, an Increase of 6% Year-over-Y
Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress REHOVOT, Israel - May 18, 2020 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Ma
Read more →KMDAKamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020
REHOVOT, Israel, May 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on M
Read more →KMDAKamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product Kamada is Responsible for Pr
Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Immunoglobulin Product Rehovot, Israel and Castelvecchio Pascoli, Italy April 27, 2020 - Kamada Ltd. (NASDAQ & TASE:
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel Notice of Results of the Extraordinary General Meeting of Shareholders held on
Weizmann Science Park Rehovot 7670402, Israel Notice of Results of the Extraordinary General Meeting of Shareholders held on March 25, 2020 Kamada Ltd. (the "Company") today announced that all of the proposals presented for approval at its Extraordinary General Meeting of Sha
Read more →KMDAKamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs K
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs Rehovot, Israel, March 11, 2020 - Kamada Ltd. (NASDAQ & T
Read more →KMDAKamada Files Annual Report for the Year Ended December 31, 2019
REHOVOT, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.S. Securities and Exchange Co
Read more →KMDAKAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend an Extraordinary Genera
Weizmann Science Park Rehovot 7670402, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING We cordially invite you to attend an Extraordinary General Meeting of Shareholders of Kamada Ltd. (the "Meeting") to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehov
Read more →KMDAKamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019 Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018 Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared t
Reports Financial Results for Fourth Quarter and Fiscal Year 2019 Israel - February 12, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months and 12 months ended December 31, 2019.
Read more →KMDAKamada Announces $25 Million Private Placement with FIMI Opportunity Fund Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada's Growth Plans and Execut
Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada's Growth Plans and Execution of Strategic Business Rehovot, Israel - January 21,
Read more →KMDAKamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Compan
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company's Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue t
Read more →KMDAKamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial evaluating the safety and ef
Read more →KMDAKamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product
Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023 Based on current market sales volume, the new product is estimated to add approximately $8 million to $10 mill
Read more →KMDAKamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel
REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Isr
Read more →KMDAKamada Reports Financial Results for Third Quarter and First Nine Months of 2019
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018. As a Reminder, Kamada’s Third Quarter 2018 Performance was Impacted by the Then Labor
Read more →KMDAKamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13
REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S
Read more →KMDAKamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at the Upcoming 2019 Rabies In The Americas (RITA) Conference REHOVOT, Israel and FORT LEE, N
Read more →KMDAKamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference
REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, be
Read more →KMDAKamada Announces Extension of GLASSIA [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada Projects to Receive Royalties from Takeda in the Range of $1
Read more →KMDAKamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda
REHOVOT, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period prior to transitioning the manufacture of GLASSIA, Kamada’s pr
Read more →KMDAKamada Reports Financial Results for Second Quarter and First Six Months of 2019
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-Year Total Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase Year-Over-Year Gross Profit for Second Quarter and First Six Months of 2019 was $13.6 million and $24.8 Mill
Read more →KMDAKamada to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6
REHOVOT, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the second quarter and six months ended June 30, 2019, prior to the open of the U.S. fin
Read more →KMDAKamada Reports Financial Results for First Quarter of 2019
Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018 Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59% Year-over-Year Adjusted EBITDA was $6.6 Million in Q1 2019, an Increase of 179% as Compared to $2.4 Million in Q1 20
Read more →KMDAKamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
REHOVOT, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the first quarter and ended March 31, 2019, prior to the open of the U.S. financial marke
Read more →KMDAKamada announces FDA acceptance of Inhaled AAT program path forward
REHOVOT, Israel, April 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company has satisfactorily add
Read more →KMDAKamada Awarded the Israeli Outstanding Exporter Award for 2017
Company received the award from the Israeli Minister of Economy and Industry for its growing export revenues For fiscal 2017, Kamada's total revenues were $102.8 Million, an increase of more than 33% compared to 2016. The company's total revenues for 2018 were $114.5 Million, an
Read more →KMDAKamada Files Annual Report for the Year Ended December 31, 2018
REHOVOT, Israel, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange
Read more →KMDAKamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
Total Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year Proprietary Products Revenues up 14% Year-Over-Year Gross Profit for 2018 Grew 29% Year-Over-Year Adjus
Read more →KMDAKamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test. Top-line Results Anticipated in H2 2019 REHOVOT,
Read more →KMDAKamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12
REHOVOT, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2018, prior to the open of the U.S
Read more →KMDAKamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
REHOVOT, Israel, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development. Dr. Ayalon has nearly 20 years of experien
Read more →KMDAKamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018
Full-Year 2018 Revenue Expected to be Between $113 Million and $115 Million Anticipated Revenues Exceed Current Revenue Guidance of $102 Million to $108 Million Expected Full-Year 2018 Total Revenue Would Represent Increase of Between 10% and 12% Over Full-Year 2017 Revenue Co
Read more →KMDAKamada Reports Financial Results for Third Quarter and First Nine Months of 2018
Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-Year Gross Profit for First Nine Months of 2018 was $20.2 million, a 1% Decrease Year-Over-Year Adjusted EBITDA was $7.4 Million in First Nine Months of 2018, an Increase of 71% Compared t
Read more →KMDAKamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12
REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2018, prior to the open of the U.S
Read more →KMDAKamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development
REHOVOT, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business de
Read more →KMDAKamada to Present Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference
REHOVOT, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conferen
Read more →KMDAKamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the
Read more →KMDAKamada Provides Updated Full-Year 2018 Revenue Guidance
As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year REHOVOT, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a pla
Read more →KMDAKamada Announces the End of the Labor Strike in the Company’s Manufacturing Facility; All Employees Returned to Work
REHOVOT, Israel, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employe
Read more →KMDAKamada Reports Financial Results for Second Quarter and First Six Months of 2018
Total Revenues for Second Quarter were $33.8 Million, a 4% Increase Over Second Quarter of 2017 Total Revenues for First Half of 2018 were $51.3 Million, a 16% Increase Over First Half of 2017 Gross Profit for First Half of 2018 was $17.7 million, a 26% Increase Year-Over-Year
Read more →KMDAKamada to Announce Second Quarter and Six Months Ended June 30, 2018 Financial Results and Host Conference Call on August 7
REHOVOT, Israel, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter and six months ended June 30, 2018, prior to the open of the U.S. financial
Read more →KMDAKamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT
REHOVOT, Israel, July 10, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP)
Read more →KMDAKamada Reports Financial Results for First Quarter of 2018
Reaffirming Guidance of $116 to $120 Million in Total Revenues for 2018 U.S. Launch of KEDRAB® [Human Rabies Immune Globulin (HRIG)] Represents Significant Company Milestone REHOVOT, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derive
Read more →KMDAKamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15
REHOVOT, Israel, May 09, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the U.S. financial markets on
Read more →KMDAKamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
REHOVOT, Israel, April 23, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the pro
Read more →KMDAKamada Reports Financial Results for Fourth Quarter and Full-Year 2017
Total Revenues for Fiscal 2017 were $102.8 Million, up 33% Over Fiscal 2016; Exceeded Full-Year Revenue Guidance of $100 Million Full-Year Proprietary Products Revenues up 42% Year-Over-Year Gross Profit for 2017 Grew 50% Year-Over-Year Reaffirming Guidance of $116 to $120 Mil
Read more →KMDAKamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7
REHOVOT, Israel, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that it will release financial results for the fiscal year ended December 31, 2017, prior to the
Read more →KMDAKamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
Kamada’s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications Next Interim Report Expected in H2 2018 Following Completion of One Year of Treatment Top
Read more →KMDAKamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease
Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed by Mount Sinai Acute GvHD International Consortium (MAGIC) to Identify Patients at High-Risk Kamada Received Exclusive Rights to Develop and Commercialize Alpha-1 Antitrypsin for the Preempt
Read more →KMDAKamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection
Three-Year Agreement Expected to Provide Revenues of Approximately $13 Million to Company Kamada’s Rabies Immune Globulin Recently Received FDA Approval REHOVOT, Israel, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeuti
Read more →KMDAKamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on
Read more →KMDAKamada Reports Financial Results for Third Quarter and First Nine Months of 2017
Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues in 2017 Guiding to $116 to $120 Million in Total Revenues in 2018 Conference Ca
Read more →KMDAKamada Announces Nomination of Three New Members to its Board of Directors
REHOVOT, Israel, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company Board of Directors has nominated three new directors to join the Company’s Board
Read more →KMDAKamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13
REHOVOT, Israel, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the third quarter ended September 30, 2017, prior to t
Read more →KMDAKamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
Efficacy trend was demonstrated in the pre-determined sub group of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg The positive trend was observed in this age group for all three key efficacy measures of Type-1 Diabetes No significant treatment e
Read more →KMDAKamada Announces CFO Transition
Gil Efron, Deputy CEO and CFO, to Depart Kamada at End of Year; Chaime Orlev to Assume CFO Duties REHOVOT, Israel, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announ
Read more →KMDAKamada to Present Corporate Overview at Two Investor Conferences in September
REHOVOT, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzg
Read more →KMDAKamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action
REHOVOT, Israel, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with a focus on mechanism of
Read more →KMDAKamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
REHOVOT, Israel, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the underwriters of its previously announced underwritten public offering of 3,333,334 of it
Read more →KMDAKamada Reports Financial Results for Second Quarter and First Six Months of 2017
Reaffirms Total Revenue Guidance of $100 Million for 2017 Conference Call Today at 8:30 AM ET REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced f
Read more →KMDAKamada Announces Pricing of Public Offering of Ordinary Shares
REHOVOT, Israel, July 28, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that it has priced its previously announced underwritten public offering of 3,333,334 of its ordi
Read more →KMDAKamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017
Company Expects to Record Strongest Quarterly Revenues in History Kamada Expects to Report Full Financial Results for Second Quarter and Six Months Ended June 30, 2017, and Host Conference Call on August 1, 2017 REHOVOT, Israel, July 27, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (N
Read more →KMDAKamada Announces Proposed Public Offering of Ordinary Shares
REHOVOT, Israel, July 27, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. Kamada
Read more →KMDAKamada to Host Second Quarter 2017 Financial Results Conference Call on August 1
REHOVOT, Israel, July 27, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the second quarter ended June 30, 2017 prior to the op
Read more →KMDAKamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
REHOVOT, Israel, July 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a propos
Read more →KMDAKamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
REHOVOT, Israel, June 22, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary
Read more →KMDAKamada Receives Additional Milestone Payment Under GLASSIA Exclusive Supply and Distribution Agreement with Shire
REHOVOT, Israel, June 12, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the receipt of an undisclosed additional milestone payment under the supply and distribution agre
Read more →KMDAKamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
REHOVOT, Israel, June 07, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that Kamada and Shire have agreed that the Investigational New Drug (IND) application approved by
Read more →KMDAKamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the appointment of Michal Stein, M.D., as Vice President and Medical Director for Immunology. Dr.
Read more →KMDAKamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
NESS ZIONA, Israel, May 24, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that a poster comprising updated data from the Company’s U.S. Phase 2 clinical trial of its
Read more →KMDAKamada Reports 2017 First Quarter Financial Results
Reaffirms revenue guidance of $100 million for 2017 Proprietary Products segment for 2017 projected at $76-$78 million, up at least 36% compared to 2016 Conference call today at 8:30 am Eastern Time NESS ZIONA, Israel, May 16, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA)
Read more →KMDAKamada to Host First Quarter 2017 Financial Results Conference Call on May 16
NESS ZIONA, Israel, May 08, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the first quarter ended March 31, 2017 prior to the
Read more →KMDAKamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)
NESS ZIONA, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on Ma
Read more →KMDAKamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
NESS ZIONA, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study
Read more →KMDAKamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors
NESS ZIONA, Israel, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the appointment of Gwen A. Melincoff to the Company’s Board of Directors. Ms. Melincoff has ov
Read more →KMDAKamada Reports Financial Results for the Fourth Quarter and Full-Year 2016
Total revenues for 2016 were $77.5 million, an 11% increase over 2015 Full year 2016 Proprietary Product revenues up over 30% Reaffirms revenue guidance of $100 million for 2017 Conference Call Today at 8:30am Eastern Time NESS ZIONA, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) --
Read more →KMDAKamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6
NESS ZIONA, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the fiscal year ended December 31, 2016 prior to th
Read more →KMDAKamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease
NESS ZIONA, Israel, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the positive Scientific Advice response from the Committee for Medicinal Products for Human Us
Read more →KMDAKamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin
NESS ZIONA, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA) a plasma-derived protein therapeutics company focused on orphan indications, announced today that it has signed a collaboration agreement with Yissum Research Development Company of the He
Read more →KMDAKamada Reports Financial Results for the Third Quarter and Nine Months of 2016
Total Revenues for Third Quarter 2016 Grew 21% to $19.4 Million vs. Third Quarter 2015 Proprietary Products Revenue Grew 57% to $15.0 Million in Third Quarter 2016 vs. Third Quarter 2015 Company Reiterates 2016 Revenue Guidance of $75 to $80 Million and 2017 Revenue Target of $
Read more →KMDAKamada to Host Third Quarter Financial Results Conference Call on November 10, 2016 at 8:30 am Eastern Time
NESS ZIONA, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the third quarter ended September 30, 2016 prior to the open of the U
Read more →KMDAKamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
NESS ZIONA, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the clinical plan for the initiation of a Phase 2/3 clinical trial in the United States of its
Read more →KMDAKamada Announces Extension of GLASSIA Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020
NESS ZIONA, Israel, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the extension of the strategic partnership with Shire plc (LSE:SHP) (NASDAQ:SHPG) for GLASSIA®
Read more →KMDAKamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference
NESS ZIONA, Israel, Sept. 09, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that its Chief Financial Officer, Gil Efron, and Vice President and Medical Director, Eran Sc
Read more →KMDAKamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA On approval by FDA, the product will represent a new option in a market where supply of post-exposure rabies t
Read more →KMDAKamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
Company’s Inhaled AAT Demonstrated Significant Increase in Endothelial Lining Fluid Inhibitory Capacity Study Results Also Showed that Inhaled AAT is the Most Efficient Way of Delivering Therapeutic Amounts of AAT to the Primary Sites of Potential Lung Injury Kamada to Utilize
Read more →KMDAKamada Reports Financial Results for the Second Quarter and First Six Months of 2016
Total Revenues for First Half of 2016 Grew 20% to $33.9 Million vs. First Half of 2015 Proprietary Products Revenue Grew 46% to $23.2 Million in First Half of 2016 vs. First Half of 2015 Company Reiterates 2016 Revenue Guidance and 2017 Sales Target of $100 Million Conference
Read more →KMDAKamada to Host Second Quarter Financial Results Conference Call on August 2, 2016 at 8:30 am Eastern Time
NESS ZIONA, Israel, July 26, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the second quarter ended June 30, 2016 prior to the open of the U.S.
Read more →KMDAKamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases
NESS ZIONA, Israel, June 23, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the appointment of Naveh Tov, M.D., Ph.D., to the position of Vice President, Clinical Develop
Read more →KMDAKamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
NESS ZIONA, Israel and NEW YORK, May 25, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, and myTomorrows, a provider of services to patients and physicians in need of diagnostic tests and
Read more →KMDAKamada Ltd. [KMDA] to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Kamada Ltd. [KMDA], a plasma-derived protein therapeutics company focused on orphan indications, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, David Tsur, Co-Founder and Chief Executive Officer, will ring
Read more →KMDAKAMADA LTD. 7 Sapir Street Kiryat Weizmann Science Park P.O Box 4081 Ness Ziona 74140, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Dear Shareholders: We cordially invite you to attend an Extraordinary
Kiryat Weizmann Science Park Ness Ziona 74140, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS We cordially invite you to attend an Extraordinary General Meeting of Shareholders of Kamada Ltd. to be held at our offices at 7 Sapir Street, Kiryat Weizmann Science
Read more →KMDADisclosure for debenture holders as of
Disclosure for debenture holders as Israeli Securities Law Regulations (Periodic and Immediate Reports) 38e Principal payments Gross interest payments (without deduction of tax) Total ILS First year * 20,023,318 6,648,036 26,671,354 Second year 40,000,000 4,431,888 44,431,88
Read more →KMDAKamada to Present at the Piper Jaffray 20th Annual 'Unplugged' Health Care Conference
NESS ZIONA, Israel, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Weizmann Science Park -- Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that David Tsur, President, Founder and Ch
Read more →KMDAKamada Signs an Additional Long-term Supply Agreement for Raw Material to Manufacture Alpha-1 Antitrypsin
NESS ZIONA, Israel, Nov. 10, 2008 (GLOBE NEWSWIRE) -- Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has signed a long-term supply agreement with a multi-nation
Read more →Competitive Position
How KMDA ranks across every disease it competes inCompetitive Position is a premium feature
See how KMDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial